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1. INTRODUCTION {#pace13659-sec-0040}
===============

Cardiac resynchronization therapy (CRT) is an established therapy for patients with heart failure (HF), impaired left ventricular (LV) function, and a wide QRS complex.[1](#pace13659-bib-0001){ref-type="ref"} Some observational studies have suggested that CRT may be undermined by renal dysfunction.[2](#pace13659-bib-0002){ref-type="ref"}, [3](#pace13659-bib-0003){ref-type="ref"} In the "real world," more than half of patients with HF have chronic kidney disease (CKD) stages 3--5.[4](#pace13659-bib-0004){ref-type="ref"}

The higher risk of sudden cardiac death (SCD) in CKD[5](#pace13659-bib-0005){ref-type="ref"}, [6](#pace13659-bib-0006){ref-type="ref"} enhances the "substrate" for defibrillation. In keeping with the hypothesis that the "sickest benefit the most,"[7](#pace13659-bib-0007){ref-type="ref"} the proportional benefit of CRT‐defibrillation (CRT‐D) should be greater in patients with CKD. There is, however, uncertainty as to the benefit of implantable‐cardioverter defibrillators (ICDs) in patients with CKD.[8](#pace13659-bib-0008){ref-type="ref"} In this respect, a meta‐analysis of patient‐level data from three randomized trials of primary prevention ICD found no benefit of ICD among 1,040 patients with estimated glomerular filtration rate (eGFR) \< 60 mL/min.[9](#pace13659-bib-0009){ref-type="ref"} Comparisons between CRT‐D and CRT‐pacing (CRT‐P) in patients with CKD have not been undertaken.

In this observational study of real‐world clinical practice, we have assessed the long‐term outcomes of CRT according to preimplant renal function. Because of the restrictions on CRT‐D placed by national guidelines,[10](#pace13659-bib-0010){ref-type="ref"} our study population comprises a substantial proportion of CRT‐P recipients. This provides a unique opportunity for a comparison of long‐term outcomes of CRT‐D and CRT‐P.

2. METHODS {#pace13659-sec-0050}
==========

The study population consisted of patients undergoing a successful CRT device implantation for primary prevention in the period from October 2005 to January 2017 at two centers (Good Hope Hospital and Queen Elizabeth Hospital, Birmingham, United Kingdom). Device choice was governed by the National Institute of Clinical Excellence guidelines, which in 2007 recommended CRT‐P rather than CRT‐D for patients with nonischemic cardiomyopathy and indications for CRT. With a subsequent guideline change in 2014 recommending CRT‐D in nonischemic cardiomyopathy,[10](#pace13659-bib-0010){ref-type="ref"} the proportion of CRT‐D recipients increased thereafter. The study was approved by the local Ethics Committee or the local Clinical Audit Departments, which do not require informed consent for audits of clinical care delivery and outcomes. The study conforms with the Declaration of Helsinki.

The diagnosis of HF was made on the basis of clinical features plus echocardiographic evidence of LV systolic dysfunction. The etiology of HF was based on the findings from a clinical history (myocardial infarction, coronary revascularization) and/or investigations (e.g., cardiovascular magnetic resonance and nuclear imaging). Patients with hypertrophic or restrictive cardiomyopathy, primary valvular disease, sarcoidosis, amyloidosis, congenital heart disease, or myocarditis were excluded. Patients who were recruited to clinical trials were also excluded.

2.1. Device therapy {#pace13659-sec-0060}
-------------------

Standard transvenous techniques under local anesthesia and intravenous sedation were used for device implantation. Thereafter, patients were followed‐up in dedicated device therapy clinics on a 6‐monthly basis; patients with events were assessed opportunistically according to clinical need. Device optimization using transmitral Doppler‐directed optimization of atrioventricular delay using an iterative technique was undertaken up to 2013. In light of emerging evidence, routine echocardiographic optimization was abandoned. Thereafter, optimization was only undertaken in symptomatic nonresponders. In patients in sinus rhythm, backup atrial pacing was set at 60 beats/min, and the pacing mode was set to DDDR with an interventricular delay of 0--4 ms. In patients with permanent atrial fibrillation, right ventricular and LV leads were implanted and a CRT generator was used, plugging the atrial port and programming to a ventricular triggered mode. Atrioventricular junction ablation was undertaken according to the physicians' discretion.

2.2. Endpoints {#pace13659-sec-0070}
--------------

The primary endpoint was total mortality. Secondary endpoints included: cardiac mortality, which included cardiac transplantation or implantation of a LV assist device; the composite endpoint of total mortality or HF hospitalization; and the composite endpoint of total mortality or unplanned hospitalization for major adverse cardiac events (MACEs), which included hospitalization for HF, myocardial infarction, acute coronary syndrome, and arrhythmia (ventricular tachycardia, ventricular fibrillation, and atrial fibrillation). Stroke and pulmonary embolism were not considered as MACEs. Therapies delivered by CRT‐D devices (antitachycardia pacing and shocks) were evaluated for appropriateness using electrograms. Only appropriate therapies were considered. In composite endpoints, the first event was used for censoring. Mortality data were collected through medical records and from interviews with patients' caregivers. Clinical events were collected every 6 months by investigators who were blinded to all other patient data, apart from demographics. These were adjudicated by blinded investigators on a 6‐monthly basis.

2.3. Renal function {#pace13659-sec-0080}
-------------------

The GFR was estimated (eGFR) using the simplified formula derived from the Modification of Diet in Renal Disease (MDRD) study, which has been validated in patients with HF.[11](#pace13659-bib-0011){ref-type="ref"} In data analysis, we have used the eGFR threshold of \<60 mL/min per 1.73 m^2^ in the definition of renal dysfunction. This cut‐off has been used extensively in CRT studies.[12](#pace13659-bib-0012){ref-type="ref"}, [13](#pace13659-bib-0013){ref-type="ref"}, [14](#pace13659-bib-0014){ref-type="ref"}

2.4. Statistical analysis {#pace13659-sec-0090}
-------------------------

Baseline characteristics were compared between patients with eGFR \< 60 and ≥ 60 mL/min per 1.73 m^2^ as well as across device types. Continuous variables were expressed as mean ± standard deviation. Normality was tested using the Shapiro‐Wilk test. Comparisons between normally distributed continuous variables were analyzed using analysis of variance and categorical variables were analyzed using χ^2^ tests. Kaplan‐Meier curves and the log‐rank test were used to assess cumulative survival. Multivariate Cox proportional hazard models were used to assess relative hazard rates comparing eGFR \<60 and ≥60 mL/min per 1.73 m^2^ as well as the impact of eGFR as a continuous measurement. Variables with a P \< 0.10 on univariable analyses were entered in multivariate models, and further backward elimination was applied for the final multivariate models. Interactions between eGFR and device type was tested and interaction P‐values for CRT‐D versus CRT‐P were reported for the two eGFR groups. Proportionality hypotheses were verified by visual examination of log (survival) graphs to ensure parallel slopes and by examining Schoenfeld residuals. In P‐spline analyses, predicted risks of total mortality were calculated considering eGFR as a continuous variable and an eGFR of 60 mL/min per 1.73 m^2^ was used as reference. Separate analyses were undertaken for the interaction between CRT‐D and CRT‐P. Statistical analyses were undertaken using Stata 14 (StataCorp, College Station, TX, USA). A two‐sided P ≤ 0.05 was considered statistically significant.

3. RESULTS {#pace13659-sec-0100}
==========

3.1. Baseline characteristics according to renal function {#pace13659-sec-0110}
---------------------------------------------------------

Of a total of 1,046 patients, 488 (42.8%) had a preimplant eGFR ≥ 60 and 598 (57.2%) an eGFR \< 60. As shown in Table [1](#pace13659-tbl-0001){ref-type="table"}, patients in eGFR \< 60 were 6.8 years older (P \< 0.001); were less likely to receive a CRT‐D (P = 0.026); and were more likely to have ischemic cardiomyopathy (P = 0.001), diabetes (P = 0.030), hypertension (P = 0.009), a previous coronary artery bypass grafting (P = 0.004), and atrial fibrillation (P = 0.009). In addition, the eGFR \< 60 group had a higher uptake of loop diuretics (P = 0.018) and a lower uptake of angiotensin‐converting enzyme inhibitors/angiotensin receptor antagonists (P \< 0.001). The two groups were well matched for sex, New York Heart Association (NYHA) class, upgrade from pacemakers, QRS morphology, QRS duration, left ventricular ejection fraction (LVEF), as well as uptake of beta‐blockers and mineralocorticoid receptor antagonists.

###### 

Baseline characteristics

                                      All            eGFR ≥ 60      eGFR \< 60     P\*       CRT‐D          CRT‐P          P\*
  ----------------------------------- -------------- -------------- -------------- --------- -------------- -------------- ---------
  N                                   1,046          448            598                      410            636            \<0.001
  eGFR (mL/min per 1.73 m^2^)         57.1 ± 20.2    75.9 ± 12.7    43.1 ± 11.8    \<0.001   58.7 ± 19.8    56.1 ± 20.6    0.042
  eGFR ≥ 60                           --             --             --             --        193 (47.07)    255 (40.09)    0.026
  eGFR \< 60                          --             --             --             --        217 (52.93)    381 (59.91)    
  Sex (male), n (%)                   756 (72.28)    331 (73.88)    425 (71.07)    0.314     322 (78.54)    434 (68.24)    \<0.001
  Age, years                          72.8 ± 10.8    68.9 ± 11.5    75.7 ± 9.2     \<0.001   70.0 ± 9.8     74.6 ± 11.1    \<0.001
  ≤59                                 130 (12.43)    94 (20.98)     36 (6.02)      \<0.001   61 (14.88)     69 (10.85)     \<0.001
  60--69                              260 (24.86)    139 (31.03)    121 (20.23)              133 (32.44)    127 (19.97)    
  70--79                              377 (36.04)    135 (30.13)    242 (40.47)              161 (39.27)    216 (33.96)    
  ≥80                                 279 (26.67)    80 (17.86)     199 (33.28)              55 (13.41)     224 (35.22)    
  NYHA class                                                                                                               
  I                                   50 (4.82)      26 (5.84)      24 (4.05)      0.120     33 (8.13)      17 (2.69)      \<0.001
  II                                  133 (12.83)    64 (14.38)     69 (11.66)               63 (15.52)     70 (11.09)     
  III                                 723 (69.72)    308 (69.21)    415 (70.10)              281 (69.21)    442 (70.05)    
  IV                                  131 (12.63)    47 (10.56)     84 (14.19)               29 (7.14)      102 (16.16)    
  Device type, n (%)                                                                                                       
  CRT‐D                               410 (39.20)    193 (43.08)    217 (36.29)    0.026     --             --             --
  CRT‐P                               636 (60.80)    255 (56.92)    381 (63.71)              --             --             --
  Upgrade from pacemaker              174 (16.63)    71 (15.85)     103 (17.22)    0.554     48 (11.71)     126 (19.81)    0.001
  Etiology of cardiomyopathy, n (%)                                                                                        
  Ischemic                            561 (53.63)    213 (47.54)    348 (58.19)    0.001     300 (73.17)    261 (41.04)    \<0.001
  Nonischemic                         485 (46.37)    235 (52.46)    250 (41.81)              110 (26.83)    375 (58.96)    
  Comorbidities, n (%)                                                                                                     
  Diabetes mellitus                   237 (22.66)    87 (19.42)     150 (25.08)    0.030     102 (24.88)    134 (21.07)    0.150
  Hypertension                        311 (29.73)    114 (25.45)    197 (32.94)    0.009     108 (26.34)    203 (31.92)    0.054
  CABG                                193 (18.45)    65 (14.51)     128 (21.40)    0.004     102 (24.88)    91 (14.31)     \<0.001
  ECG variables                                                                                                            
  Sinus rhythm, n (%)                 701 (67.02)    320 (71.43)    381 (63.71)    0.009     296 (72.20)    405 (63.68)    0.004
  Atrial fibrillation, n (%) †        345 (32.98)    128 (28.57)    217 (36.29)              114 (27.80)    231 (36.32)    
  QRS morphology (LBBB), n (%)        828 (79.69)    357 (80.04)    471 (79.43)    0.806     322 (78.92)    506 (80.19)    0.620
  QRS duration (ms)                   154.9 ± 23.2   154.5 ± 22.4   155.2 ± 23.8   0.662     152.7 ± 23.1   156.3 ± 23.1   0.015
  Medication, n (%)                                                                                                        
  Loop diuretics                      991 (94.74)    416 (92.86)    575 (96.15)    0.018     398 (97.07)    593 (93.24)    0.007
  ACEIs/ARAs                          923 (88.24)    419 (93.53)    504 (84.28)    \<0.001   381 (92.93)    542 (85.22)    \<0.001
  Beta‐blockers                       720 (68.83)    311 (69.42)    409 (68.39)    0.723     315 (76.83)    405 (63.68)    \<0.001
  MRAs                                431 (41.20)    188 (41.96)    243 (40.64)    0.666     207 (50.49)    224 (35.22)    \<0.001
  LVEF (%)                            24.8 ± 9.8     25.1 ± 9.5     24.5 ± 10.0    0.338     23.7 ± 9.0     25.5 ± 10.2    0.006

*Note*: Patients were grouped according to preimplant estimated glomerular filtration rate (eGFR) \< 60 or ≥ 60 mL/min per 1.73 m^2^ and device type. Variables are expressed as mean ± standard deviation, unless indicated otherwise. \* refers to differences between the groups from analysis of variance for continuous variables and from χ^2^ tests for categorical variables; † includes permanent, persistent, and paroxysmal atrial fibrillation (AF).

ACEIs = angiotensin‐converting enzyme inhibitors; ARAs = angiotensin receptor blockers; CABG = coronary artery bypass grafting; CRT‐D = cardiac resynchronization therapy‐defibrillation; CRT‐P = cardiac resynchronization therapy‐pacing; ECG = electrocardiogram; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonists; NYHA = New York Heart Association.

John Wiley & Sons, Ltd.

3.2. Outcomes according to renal function {#pace13659-sec-0120}
-----------------------------------------

As shown in Figure [1](#pace13659-fig-0001){ref-type="fig"}, patients with eGFR \< 60 had a higher total mortality, total mortality or HF hospitalization, total mortality or hospitalization for MACEs, and cardiac mortality. Total mortality was 273/598 (45.7%) (14.0 per 100 person‐years) in the eGFR \< 60 group and 162/488 (33.2%) (9.11 per 100 person‐years) in the eGFR ≥ 60 group (Supplementary [Table S1](#pace13659-supl-0001){ref-type="supplementary-material"}, Online Appendix). Over a maximum follow‐up period of 12 years (median of 3.7 years (interquartile range \[IQR\]: 2.1--5.7; 3.4 years \[IQR, 1.9--5.4\] for eGFR \< 60 and 3.9 years \[IQR: 2.2--6.0\] years for eGFR ≥ 60), the eGFR \< 60 group had a higher risk of total mortality (hazard ratio \[HR\]: 1.53; 95% confidence interval \[CI\]: 1.26--1.86), total mortality or HF hospitalization (HR: 1.55; 95% CI: 1.29--1.86), total mortality or hospitalization for MACEs (HR: 1.51; 95% CI: 1.26--1.80), and cardiac mortality (HR: 1.55; 95% CI: 1.23‐1.95). Analyses of crude HRs of total mortality and of eGFR in subgroups is shown in Supplementary [Figure S1](#pace13659-supl-0001){ref-type="supplementary-material"}, Online Appendix.

![Primary and secondary endpoints according to renal function. Kaplan‐Meier survival curves for clinical outcomes according to renal function. Patients were grouped according to an eGFR \< or ≥ 60 mL/min per 1.73 m^2^. CRT‐D = cardiac resynchronization therapy‐defibrillation; CRT‐P = cardiac resynchronization therapy‐pacing; eGFR = estimated glomerular filtration rate; HF = heart failure; MACE = major adverse cardiovascular events \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](PACE-42-595-g001){#pace13659-fig-0001}

The survival benefit of eGFR ≥ 60 was seen in most subgroups except for age \< 59 or ≥ 80 years, female sex, NYHA class IV, with diabetes, and LVEF ≤ 0.25. In multivariate analyses (Table [2](#pace13659-tbl-0002){ref-type="table"}), the eGFR \< 60 group had a higher risk of total mortality (adjusted HR \[aHR\]: 1.28; 95% CI: 1.04--1.57), total mortality or HF hospitalization (aHR: 1.32; 95% CI: 1.09--1.59), total mortality or hospitalization for MACEs (aHR: 1.34; 95% CI: 1.11--1.61), and cardiac mortality (aHR: 1.33; 95% CI: 1.02--1.74), after covariate adjustment. When eGFR was considered as continuous variable, an eGFR decrement of 10 mL/min per 1.73 m^2^ was associated with a higher total mortality (aHR: 1.09; 95% CI: 1.04--1.15), a higher total mortality or HF hospitalization (aHR: 1.11; 95% CI: 1.05--1.16), and a higher total mortality or hospitalization for MACEs (aHR: 1.10; 95% CI: 1.05‐1.15), after covariate adjustment.

###### 

Multivariate analyses

                        Total mortality   Total mortality or HF hospitalization   Total mortality or MACEs   Cardiac mortality                                                                                            
  --------------------- ----------------- --------------------------------------- -------------------------- ------------------- ------- ------- ------- --------- ------- ------- ------ --------- ------- ------ ------ ---------
  eGFR \< 60            1.28              1.04                                    1.57                       0.017               1.32    1.09    1.59    0.004     1.34    1.11    1.61   0.002     1.33    1.02   1.74   0.036
  Sex (male)            1.70              1.34                                    2.16                       \<0.001             1.51    1.22    1.88    \<0.001   1.47    1.19    1.81   \<0.001   1.68    1.22   2.32   0.002
  Age (years)           1.03              1.02                                    1.04                       \<0.001             1.02    1.01    1.03    \<0.001   1.02    1.01    1.03   0.001     1.02    1.00   1.03   0.029
  NYHA class                                                                                                                                                                                                              
  III                   1.77              1.17                                    2.68                       0.007               1.44    1.03    2.03    0.035     1.51    1.08    2.11   0.017     --                    
  IV                    3.85              2.47                                    6.00                       \<0.001             3.13    2.15    4.57    \<0.001   3.08    2.12    4.48   \<0.001   2.51    1.85   3.40   \<0.001
  Device type (CRT‐D)   0.67              0.53                                    0.84                       0.001               0.70    0.57    0.87    0.001     0.72    0.58    0.89   0.002     0.64    0.47   0.87   0.004
  Etiology (ischemic)   1.24              1.00                                    1.53                       0.049               1.29    1.06    1.58    0.012     1.39    1.14    1.69   0.001     1.41    1.06   1.87   0.017
  Diabetes mellitus     --                1.26                                    1.02                       1.55                0.033   1.25    1.02    1.54      0.034   1.40    1.06   1.87      0.020                 
  Atrial fibrillation   --                --                                      --                         1.30                0.99    1.70    0.057                                                                    
  QRS duration (ms)     0.99              0.99                                    1.00                       0.004               0.99    0.99    1.00    \<0.001   0.99    0.99    1.00   \<0.001   0.99    0.98   1.00   0.001
  Loop diuretics        --                1.56                                    1.01                       2.42                0.046   --      --                                                                       
  Beta‐blockers         --                --                                      0.82                       0.68                0.98    0.032   0.77    0.59      1.00    0.047                                          
  LVEF (%)              --                --                                      --                         0.98                0.97    1.00    0.008                                                                    

*Note*: Data are expressed in terms of hazard ratios (HR) and 95% confidence intervals (95% CI). CRT‐D = cardiac resynchronization therapy‐defibrillation; CRT‐P = cardiac resynchronization therapy‐pacing; HF = heart failure; LVEF = left ventricular ejection fraction; MACE = major adverse cardiovascular events; NYHA = New York Heart Association.

John Wiley & Sons, Ltd.

3.3. Baseline characteristics according to device type {#pace13659-sec-0130}
------------------------------------------------------

Over the study period, 1,046 patients underwent primary prevention CRT‐D (n = 410 \[39.2%\]) or CRT‐P (n = 636 \[60.8%\]). As shown in Table [1](#pace13659-tbl-0001){ref-type="table"}, significant differences emerged between CRT‐D and CRT‐P patients with respect to most baseline characteristics. Notably, CRT‐D patients were 4.6 years younger (P \< 0.001) and a greater proportion were men (P \< 0.001). In addition, CRT‐D patients had a lower NYHA class (76.4% in class III or IV, compared with 86.2% in CRT‐P patients, P \< 0.001) and a higher eGFR (by 2.6 mL/min per 1.73 m^2^, P = 0.042).

3.4. Outcomes according to device type {#pace13659-sec-0140}
--------------------------------------

In univariate analyses, CRT‐D patients had a lower crude total mortality (HR: 0.68; 95% CI: 0.55--0.84), total mortality or HF hospitalization (HR: 0.73; 95% CI: 0.60--0.88), total mortality or hospitalization for MACEs (HR: 0.74; 95% CI: 0.62--0.90), and cardiac mortality (HR: 0.67; 95% CI: 0.52--0.86). Figure [2](#pace13659-fig-0002){ref-type="fig"} shows that the benefit of CRT‐D over CRT‐P was evident for both the eGFR \< 60 and ≥ 60 groups.

![Primary and secondary endpoints according to device type and renal function. Kaplan‐Meier survival curves for clinical outcomes according to device type, in the categories of renal function according to an eGFR \< or ≥ 60 mL/min per 1.73 m^2^. CRT‐D = cardiac resynchronization therapy‐defibrillation; CRT‐P = cardiac resynchronization therapy‐pacing; eGFR = estimated glomerular filtration rate; HF = heart failure; MACE = major adverse cardiovascular events \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](PACE-42-595-g002){#pace13659-fig-0002}

In multivariate analyses (Table [2](#pace13659-tbl-0002){ref-type="table"}), CRT‐D was associated with a lower total mortality in both the eGFR groups (eGFR ≥ 60 aHR: 0.65; 95% CI: 0.45--0.95; eGFR \< 60 aHR: 0.64; 95% CI: 0.48--0.85). A similar trend was observed for total mortality or HF hospitalization, total mortality or hospitalization for MACEs, and cardiac mortality. We did not find any device type/eGFR interaction when comparing CRT‐D with CRT‐P (all P \> 0.5) (Supplementary [Table S2](#pace13659-supl-0001){ref-type="supplementary-material"}, Online Appendix). The relative risks of total mortality increased and difference between CRT‐D and CRT‐P narrowed as the eGFR decreased below 60 (Supplementary [Figure S2](#pace13659-supl-0001){ref-type="supplementary-material"}, Online Appendix).

To explore possible effects of date of implantation on outcomes, we used different year dummies on survival analyses and found that date of implantation did not predict any of the endpoints (data not shown).

4. DISCUSSION {#pace13659-sec-0150}
=============

This is the largest study comparing mortality and morbidity after CRT‐D and CRT‐P in relation to preimplant renal function. We found that an eGFR \< 60 was associated with a higher risk of total mortality, total mortality or HF hospitalization, total mortality or hospitalization for MACE, and cardiac mortality, compared to eGFR ≥ 60. Moreover, despite less favorable outcomes compared to the eGFR ≥ 60 group, CRT‐D was associated with a lower total mortality and composite endpoints in the eGFR \< 60 group.

4.1. Renal function and outcomes {#pace13659-sec-0160}
--------------------------------

We have observed that CKD was associated with a higher total mortality. Every 10 mL/min per 1.73 m^2^ decrement in eGFR was associated with a 15% higher crude total mortality (9% after covariate adjustment). This is broadly consistent with several observational studies. In a registry of 716 consecutive CRT recipients, a 10 mL/min per 1.73 m^2^ decrement in eGFR was associated with an 18% higher total mortality.[15](#pace13659-bib-0015){ref-type="ref"} In a study of 432 CRT‐D recipients, the estimated 5‐year mortality rose from 36.3% for CKD stage 1 to 62.1% for CKD stages 4 and 5.[16](#pace13659-bib-0016){ref-type="ref"} In the National Cardiovascular Data Registry (ICD Registry), the 3‐year mortality for CRT‐D patients with end‐stage renal failure was 54%.[2](#pace13659-bib-0002){ref-type="ref"}

In subgroup analyses (Figure [2](#pace13659-fig-0002){ref-type="fig"}), the survival benefit of eGFR ≥ 60 was seen in most subgroups on total mortality, except for age (\<59 years or ≥80 years), female sex, NYHA class IV, diabetes, or LVEF \< 25%. With respect to female sex, several studies have shown a more favorable outcome from device therapy in women,[17](#pace13659-bib-0017){ref-type="ref"}, [18](#pace13659-bib-0018){ref-type="ref"}, [19](#pace13659-bib-0019){ref-type="ref"} and it appears that the protective effect of female sex somehow overrides the effects of renal dysfunction. With respect to age, it is conceivable that the natural mortality expected at the age of ≥80 years overrides the effects of renal dysfunction. Arguably, severe pump failure, in the context of NYHA class IV or a LVEF \< 25%, may also be expected to override renal dysfunction.

4.2. CRT‐D versus CRT‐P {#pace13659-sec-0170}
-----------------------

We found that CRT‐D was superior to CRT‐P with respect total mortality, total mortality or HF hospitalization, total mortality or hospitalization for MACEs, and cardiac mortality. Importantly, the lower risk of these endpoints with CRT‐D over CRT‐P was evident in patients with an eGFR \< 60, despite that these outcomes were worse than in the eGFR ≥ 60 group. This suggests that in CRT recipients, CRT‐D is superior to CRT‐P, regardless of renal function.

A subanalysis of MADIT‐CRT (Multicenter Automatic Defibrillator Implantation Trial‐Cardiac Resynchronization Therapy) showed that although total mortality was higher in patients with an GFR \< 60, compared to patients with an eGFR ≥ 60, the reduction in total mortality and total mortality or HF hospitalization was actually greater in the GFR \< 60 group.[12](#pace13659-bib-0012){ref-type="ref"} Importantly, MADIT‐CRT compared CRT‐D with ICD and, therefore, the reported findings relate to the effects resynchronization rather than defibrillation. In this study, which compares CRT‐D versus CRT‐P rather than CRT‐D with ICD, the superior outcomes of CRT‐D must, intuitively, be due to delivered antitachycardia pacing and shocks. However, the rate of delivered therapies was similar in both the eGFR groups. Why the same rate of such therapies should translate to better outcomes, in terms of total and cardiac mortality, even in patients with an eGFR \< 60, is not immediately apparent. The possibility arises that, over and above the benefits of CRT, antitachycardia pacing or shocks carry a greater proportional survival advantage in advanced CKD (eGFR \< 60).

4.3. Clinical application {#pace13659-sec-0180}
-------------------------

Physicians may be tempted to avoid device therapy in patients with renal dysfunction,[20](#pace13659-bib-0020){ref-type="ref"} given reports of poor outcomes and an increased risk of complications.[2](#pace13659-bib-0002){ref-type="ref"} This study shows that after CRT, patients with CKD had a worse prognosis than patients with normal or mildly impaired renal function. Nevertheless, patients lived longer and were less likely to be hospitalized for HF or MACE after CRT‐D than after CRT‐P. These findings support the preferential use of CRT‐D over CRT‐P in patients with moderate CKD.

4.4. Limitations {#pace13659-sec-0190}
----------------

This study has the limitations of an observational study. We did not include patients without CRT‐D or CRT‐P therapy as a control group and we cannot therefore comment on the relative benefit of device therapy over optimal medical therapy. Although we have included more patients with severe renal dysfunction than any other study (n = 84 with eGFR \< 30 or end‐stage renal failure), we lack statistical power to adequately compare CRT‐D versus CRT‐P in patients at these extremes of renal dysfunction. In addition, it is possible that renal dysfunction influenced the prescription and choice of device therapy, which was based on physician\'s decisions rather than by study design. The national guidelines on CRT represent an *a priori* selection bias on device type selection which may have influenced outcomes. Notwithstanding, the group difference in eGFR was only marginal (2.6 mL/min per 1.73 m^2^). We have no data as to the number of patients who were excluded from device therapy on the basis of renal dysfunction. A further limitation is the lack of data with regard to optimization of medical therapy following device implantation. Unfortunately, we lack data on the exact number of clinic visits per patient, or the reasons behind them. It is possible that differences in clinical follow‐up could have influenced our results. Differences in the biventricular pacing uptake between the CRT‐D and CRT‐P groups, which were not addressed, could also account for differences in outcomes.

5. CONCLUSIONS {#pace13659-sec-0200}
==============

In CRT recipients, moderate CKD was associated with a higher total mortality and morbidity compared to normal renal function or mild CKD. Despite less favorable absolute outcomes, patients with moderate CKD had better outcomes from CRT‐D than after CRT‐P. These findings support the preferential use of CRT‐D over CRT‐P in patients with moderate CKD who are considered candidates for CRT.
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